The stock of ProMetic Life Sciences Inc. (TSE:PLI) is a huge mover today! About 640,639 shares traded hands. ProMetic Life Sciences Inc. (TSE:PLI) has declined 29.59% since April 20, 2016 and is downtrending. It has underperformed by 35.00% the S&P500.
The move comes after 7 months positive chart setup for the $1.44B company. It was reported on Nov, 24 by Barchart.com. We have $2.58 PT which if reached, will make TSE:PLI worth $57.60 million more.
ProMetic Life Sciences Inc. (TSE:PLI) Ratings Coverage
Out of 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $6.70 is the highest target while $3 is the lowest. The $5.14 average target is 107.26% above today’s ($2.48) stock price. ProMetic Life Sciences Inc. has been the topic of 24 analyst reports since August 10, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of PLI in a report on Thursday, October 27 with “Outperform” rating. The rating was maintained by RBC Capital Markets on Thursday, August 25 with “Outperform”. Scotia Capital maintained it with “Outperform” rating and $5 target price in Tuesday, November 22 report. The company was maintained on Tuesday, November 22 by RBC Capital Markets. The rating was reinitiated by Paradigm Research with “Buy” on Monday, September 28. The firm has “Outperform” rating given on Monday, August 10 by Scotia Capital. The stock has “Outperform” rating given by RBC Capital Markets on Wednesday, November 16. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, October 21 report. On Tuesday, December 8 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Outperform” rating given on Wednesday, November 16 by Scotia Capital.
Another recent and important ProMetic Life Sciences Inc. (TSE:PLI) news was published by Marketwatch.com which published an article titled: “Thomvest Asset Management Inc. reports Prometic Life Sciences Inc. share …” on March 11, 2016.
ProMetic Life Sciences Inc. is a Canada biopharmaceutical company. The company has a market cap of $1.44 billion. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.